Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 22;13(3):235-239.
doi: 10.1007/s13691-024-00668-4. eCollection 2024 Jul.

An underrecognized association: immune checkpoint inhibitor-related aortitis, a case report with the review of the literature

Reşit Yıldırım  1 , Aida Shikhaliyeva  2 , Hüseyin İçer  2 , Hakan Deveci  3 , Emre Entok  3 , Döndü Üsküdar Cansu  1 , Cengiz Korkmaz  1
Affiliations

An underrecognized association: immune checkpoint inhibitor-related aortitis, a case report with the review of the literature

Reşit Yıldırım et al. Int Cancer Conf J. .

Abstract

Immune-checkpoint inhibitors (ICIs) are considered as the novel treatment modality in certain cancers. They may soon be used widely even as the first-line option for cancer treatment due to their remarkable efficacies and impacts on survival rates, particularly in cases of advanced metastatic cancer. Of note, these agents might unveil new autoimmune diseases as well as causing flare-ups of a pre-existing autoimmune disease. Data in this field have been accumulated during recent years. Early detection and a collaborative approach are, therefore, crucial in the management of a patient who presents with any of these conditions. Herein, we report a patient with a diagnosis of metastatic renal cell cancer presented with vasculitis involvement in the aorta during nivolumab treatment. Our aim with this case is to increase the awareness of ICI-related vasculitis involvement among rheumatologists in the light of literature.

Keywords: Aortitis; Cancer treatment; Immune checkpoint inhibition.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Fig. 1
Fig. 1
PET–CT scan showed increased activity in bilateral carotid arteries and thoraco-abdominal aorta at admission
Fig. 2
Fig. 2
In the third month, activity relatively decreased but was still ongoing
Fig. 3
Fig. 3
No activity suggestive of vasculitis in the aorta and its branches was found in PET–CT imaging at month 7 of follow-up
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity [published online ahead of print, 2022 Jan 26] Nat Rev Clin Oncol. 2022;19:254–267. doi: 10.1038/s41571-022-00600-w. - DOI - PMC - PubMed
    1. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi: 10.1038/s41572-020-0160-6. - DOI - PMC - PubMed
    1. Shen P, Deng X, Hu Z, et al. Rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy. Front Med (Lausanne) 2021;8:762247. doi: 10.3389/fmed.2021.762247. - DOI - PMC - PubMed
    1. Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford) 2019;58(Suppl 7):vii68–vii74. doi: 10.1093/rheumatology/kez295. - DOI - PMC - PubMed
    1. Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37(9):2579–2584. doi: 10.1007/s10067-018-4177-0. - DOI - PubMed

LinkOut - more resources